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The Risks and Benefits of HRT before and after a Breast Cancer Diagnosis 
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Professor Richard Santen 
 
Introduction                                                                                                                                                          
This is an important and controversial topic. The risk of breast cancer diagnosis associated with 
hormone replacement therapy (HRT) is often assumed by health care professionals and the lay 
public alike to be very high, which may adversely influence decisions about its initiation and 
continuance.1 This is despite the fact that most women will not be diagnosed in their lifetime and 
any risk conferred by HRT is less than that of other postmenopausal lifestyle risk factors for breast 
cancer (e.g. obesity, alcohol).2 The impact of HRT on breast cancer diagnosis is often discussed in 
isolation of its benefits and there is no or little simultaneous reference to the other lifestyle risk 
factors for breast cancer, to provide context when counselling women about its use. This consensus 
statement provides an overview of the association between HRT and breast cancer outcomes in 
women at low and higher risk of breast cancer. It had been updated in light of the recent publication 
from the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC), which has stoked 
further concern.3 A summary of recommendations for clinical practice is provided at the end of this 
statement.  
 
HRT and the risk of being diagnosed with breast cancer, studies pre-dating the 2019 CGHFBC 
To aid interpretation of the 2019 CGHFBC, key publications pre-dating it, which have influenced UK 
HRT prescribing practice are reviewed. Those that have largely shaped clinical practice include the 
1997 CGHFBC re-analysis of 51 world-wide observational studies, the placebo-controlled, 
randomised Women’s Health Initiative Study (WHI), observational Million Women’s Study (MWS) 
and the 2015 National Institute for Health and Care and Excellence Menopause Guidance (NG23).4-8 
In considering the findings from all these studies, it is relevant to keep in mind that whilst analysis of 
large patient cohorts such as the MWS, the CGHFBC re-analyses and 2015 NG23 will produce 
statistical precision, reliability is limited due to the risk of bias and confounding inherent in 
observational methodology. The WHI placebo-controlled data is likely to provide a better estimate 
of the relative risk for HRT versus placebo. 
1. The 1997 CGHFBC established a duration-dependent association of HRT with risk of diagnosis, 
emerging after 5 years’ exposure (an overall risk ratio of 1.35). This appeared greater with 
combined rather than unopposed HRT and fell following cessation. The degree of risk with any 
HRT exposure was estimated to be equivalent to the impact of a delayed menopause (2.3% vs 
2.8% per year respectively).4  
2. In 2002 and 2004, initial findings from the randomised WHI study confirmed an overall increased 
risk of borderline significance with continuous combined HRT (i.e. 0.625mg conjugated equine 
oestrogen, CEE plus 2.5mg medroxyprogesterone acetate). Risk was not significantly increased, 
however, when subgroup analysis was performed by age group (i.e. 50 to 59, 60 to 69 and 70 to 
79 years).5 Unopposed oestrogen (i.e. 0.625mg CEE) was associated with a non-significant 
reduction in risk of diagnosis.6 These contrasting outcomes can be explained by the effect of HRT 
on the reservoir of occult hormone sensitive cancers present in the breast at the time of its 
initiation. When deprived of oestrogen long-term, breast epithelium becomes susceptible to 
oestrogen-induced apoptotsis upon oestrogen re-exposure. Hence, in hormone naïve 
postmenopausal women, commencement of unopposed oestrogen reduces the growth of any 
occult breast cancers so they take longer to reach the size threshold for diagnosis and a 
decrease in risk of diagnosis is observed. Exposure to combined HRT is hypothesised to stimulate 
occult breast cancer growth leading to them reaching their size threshold for diagnosis sooner, 
therefore risk of diagnosis is increased.9   
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3. In 2003, the observational MWS reported risk of diagnosis to be increased with all HRT 
regimens, the greatest elevation in risk associated with combined preparations. In contrast with 
all other studies, the impact of HRT was observed with short-term use risk (i.e. 6 months to less 
than 2 years).7 This erroneous finding has been attributed to ascertainment bias and 
underestimation of duration of HRT exposure. Further criticisms of the study methodology have 
been explained in detail elsewhere.10 
 
Unfortunately, whilst the degree of estimated risk with combined HRT from the randomised WHI 
was between 1.2-1.3 and that of the MWS was in keeping with the 1997 CGHFBC and other 
observational study risk estimates (i.e. up to twofold increase), the adverse publicity their results 
generated caused a significant fall in HRT prescribing world-wide. Both study investigators placed 
emphasis on use of risk ratios and percentage change in risk, which were misinterpreted and could 
have been avoided by presenting findings using absolute numbers with framing.11 
 
4. The 2015 NG23 included evaluation of the short-term outcomes of HRT, with use for up to 5 
years on breast cancer outcomes.8 The clinical studies eligible for review were mostly 
observational and ranged from low to moderate quality at best. Of randomised trials, only the 
WHI study was sufficiently powered for inclusion. Overall the findings did not differ significantly 
from those of previous evidence. 
 
Taken as a whole, clinical evidence predating the 2019 CGHFBC led to the following conclusions: 
• HRT with oestrogen alone (CEE, oestradiol, oestriol) is associated with no or little change in risk 
and may not be increased with low-dose vaginal oestrogen.8,12   
• Combined HRT, delivered by any route of administration, can be associated with an increased 
risk, which appears duration dependent.8,13,14  Evidence for the levonorgestrel intra-uterine 
system (LNG-IUS) is inconsistent.15,16 Risk may not be elevated if dydrogesterone or micronized 
progesterone are used in preference to synthetic progestogens but further confirmatory 
evidence is needed.12,13,17 
• Risk of diagnosis is not elevated in past users of HRT8 
• Risk is limited to lean women (i.e. not overweight or obese)4 
• There does not appear to be a dosage effect14  
• There is no additive effect in women at elevated personal risk due to a family history or high-risk 
benign breast condition.4.14  
• In women with premature ovarian insufficiency (POI), it is recommended that years of HRT 
exposure should be counted from the age of 50 and not at the age of HRT commencement when 
POI is diagnosed.4,18 
 
The 2019 CGHFBC 
Despite this re-analysis involving data from 58 published and unpublished, worldwide observational 
studies, the main outcomes reported were restricted to data from 24 prospective studies, which 
contributed 75% of the cases, half of these were from the widely criticised MWS. No results from the 
placebo controlled, WHI study were shown for comparison in the main paper.                                    
The main findings are as follows: 
1. The risk of breast cancer diagnosis is greater with combined than unopposed HRT 
i. In common with previous evidence, a duration-dependent increase in risk was associated with 
sequential and continuous combined preparations, risk with the latter being greater.17 
ii. The difference in absolute risk, however, between continuous and sequential combined HRT is 
small, with up to 14 years exposure an estimated excess difference of 10 additional breast 
cancer diagnoses per 1000 women aged between 50 to 59 respectively. This should be weighed 
against the risk of endometrial cancer which is significantly decreased by continuous but not 
sequential prescription of HRT.19 
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iii. As in previous studies short-term use for up to 5 years of dydrogesterone and micronized 
progesterone-containing regimens were not associated with an increased risk of diagnosis but a 
longer duration of exposure was.4,17 However, whilst increased risk with a longer duration of 
dydrogesterone use was less than that of synthetic progestogens, no meaningful conclusions can 
be drawn for micronized progesterone as the number of breast cancer events was too small for 
reliable estimation.4   
iv. Unopposed oestrogen was reported to be associated with an increased risk of breast cancer 
diagnosis, which differs with the randomised WHI study, where a decreased risk of diagnosis was 
reported with unopposed CEE.6  These apparent opposing effects of unopposed oestrogen on 
risk of diagnosis can be explained by the oestrogen deprivation hypothesis in which, the 
duration of a woman’s endogenous oestrogen depletion determines whether apoptosis of pre-
existing, occult breast cancers occurs upon oestrogen re-exposure with unopposed HRT. Short-
term oestradiol depletion is not associated with apoptosis upon re-exposure, whereas long-term 
oestradiol deprivation is.9  
a. The breast tissue in women recently postmenopausal is only short-term oestradiol deprived. 
Hence initiation of unopposed HRT does not cause apoptosis but stimulates proliferation of 
pre-existing, occult breast cancers. As this proliferative effect is much less than that of 
estrogen plus a progestogen, it takes a much longer time to detect an increased risk of 
breast cancer diagnosis with oestrogen alone. This would explain the CGHFBC finding that 
women commencing oestrogen alone shortly after the menopause appear to have no 
increase in breast cancer if used over a period of 5 years but with more prolonged use risk of 
diagnosis increases.   
b. In contrast, older postmenopausal women will have been depleted of oestradiol for longer 
and exposure to unopposed HRT stimulates apoptosis, slowing the growth of pre-existing 
occult breast cancers. As the average age of women in the WHI study was 63, this likely 
accounts for the finding of a protective effect. This appears to be supported by the CGHFBC, 
as in women over 60 at time of commencing unopposed HRT, the risk of breast cancer 
diagnosis was either not increased or reduced depending on whether analysis of prospective 
or retrospective observational studies was undertaken (relative risk 1.03, 95% CI 0.88-1.21 
vs 0.56, 95% CI 0.46-0.68). 
v. Risk with unopposed oestrogen was elevated with oral and transdermal oestrogen 
administration but unaffected by low and ultra-low dose vaginal preparations that have minimal 
systemic absorption. This concurs with previous evidence.12,17,20 
vi. There was no evidence of a dosage effect with unopposed oestrogen 
 
Table 1 compares the absolute excess risk with current HRT use from the randomised WHI, 2019 
CGHFBC and 2015 NG23. Overall, the absolute excess risk of diagnosis with HRT use is small, 
regardless of category of current use. Most women exposed to HRT will not be diagnosed with 














Absolute excess risk of breast cancer diagnosis over 10 years per 1000 women starting                  
HRT at age 50                                 
 Duration of 
HRT use 








No HRT    26 974 
Oestrogen alone  - -   
Use up to 5 yearsa      
WHI study 2013 4.6 yrs (median) 0.62 (0.32-1.18) -11 15 985 
NICE 2015 Up to 5 years 1.16 (0.95-1.42) +3 29 971 
CGHFBC 2019b < 5 years 1.16 (1.10-1.24) +3 29 971 
Use up to 10 years      
WHI study 2013 No data - - - - 
NICE 2015b 5-10 years 1.23 (0.94-1.61) +6 32 968 
CGHFBC 2019b 5-9 years 1.22 (1.17-1.28) +6 32 968 
Combined HRT 
Use up to 5 yearsa      
WHI study 2013 3.2 yrs (median) 1.06 (0.67-1.67) +4 30 970 
NICE 2015 Up to 5 years 1.52 (1.25-1.85) +8 34 966 
CGHFBC 2019 < 5 years 1.56 (1.49-1.64) +9 35 965 
Use up to 10 years      
WHI study 2013 No data - - - - 
NICE 2015c 5-10 years 1.94 (1.41-2.66) +24 50 950 
CGHFBC 2019 5-9 years 1.97 (1.90-2.04) +25 51 949 
a Absolute risks calculated over 10 years as 5 years HRT use, followed by 5 years past HRT use. 
b The risk estimate for less than five years category has been calculated by pooling the numbers for <1 year and 
one to four years duration of HRT 
exposure, using inverse variance weighting. 
c Evidence on observational estimate demonstrated very serious imprecision in the estimate of effect. 
 
2. In past users of HRT, the relative risks were lower than in current users but risks remained 
elevated more than 10 years after stopping. 
i. Most evidence prior to the 2019 CGHFBC showed a fall in risk of breast cancer diagnosis after 
HRT cessation, hence the 2015 NG23 recommendation to advise women of such.8 The 2019 
CGHFBC finding that risk persists after stopping HRT is new and associated with a longer 
duration of prior use and a longer time since cessation.3 
ii. Long-term follow-up of the randomised WHI study also showed similar trends, with an initial fall 
in risk after HRT cessation, followed by an elevated risk more than five years since stopping.21  
iii. Both sets of results can be explained by the growth promoting effect of HRT on pre-existing, 
hormone sensitive, occult breast cancers. Withdrawal of unopposed oestrogen stops oestrogen-
induced apoptosis, leading to an increase in cancer growth rate and a late-onset elevated risk of 
diagnosis, when the size threshold for diagnosis is eventually reached.  Stopping combined HRT 
slows the rate of occult cancer growth resulting in an initial fall in diagnosis, followed by a late-
onset increase, when the diagnostic size threshold is reached.9  
iv. For both unopposed and combined HRT, the absolute excess risk in past users is small and less 
than that associated with being overweight or drinking 2 or more units of alcohol per day).3, 22 
 
Table 2 shows comparative absolute risks in women with a previous duration of HRT use up to 








Absolute excess risk of breast cancer diagnosis over 10 years per 1000 women starting HRT at age 50 with 
previous HRT exposure, by duration of use and time since stopping 
Prior duration of HRT use, 5 years 
Time since 
last use 








Past use of oestrogen 
No HRT  - - 26 974 




   
WHI study 2013, 2015 2.75 yearsc 0.55 (0.34-0.89) -4 22 978 
CGHFBC 2019 < 5 yearsd 1.05 (0.96-1.16) +1 27 973 
Time since stopping 5 to 9 yearsb      
WHI study 2013, 2015 6.6 yearse 1.17 (0.73-1.87) - - - 
CGHFBC 2019 5-9 years 1.06 (0.97-1.16) +1 27 973 
Past use of combined HRT 




   
WHI study 2013, 2015 2.75 yearsc 1.23 (0.90-1.70) +8 34 966 
CGHFBC 2019 < 5 yearsd 1.13 (1.05-1.21) +2 28 972 
Time since stopping 5 to 9 yearsb      
WHI study 2013, 2015 8.2 yearse 1.37 (1.06-1.77) - - - 
CGHFBC 2019 5-9 years 1.21 (1.14-1.29) +1 27 973 
a Absolute risks calculated over 10 years as 5 years of 5 years since stopping HRT, followed by 5 years 
of 5-9 years since stopping HRT use. 
b Absolute risks calculated over 10 years as 5 years of 5-9 years since stopping HRT, followed by 5 
years of >10 years since stopping HRT use. 
c Duration of the early intervention phase post HRT cessation. 
d The risk estimate for less than five years category has been calculated by pooling the numbers for 
<1 year and one to four years duration of HRT 
exposure, using the inverse variance weighting. 
e Duration of late intervention phase in the estrogen only and combined HRT arms. 
 
3. Women who start HRT soon after menopause have an increased risk of invasive breast cancer, 
compared with never users 
i. Risk of diagnosis was found to be increased in women who commenced HRT nearer to the time 
of onset of menopause compared with those starting it more than five years since menopause. 
However, this is relatively weak evidence, not supported by the randomised WHI study, which in 
itself was probably underpowered for reliable assessment of this outcome.23 
ii. In conclusion, there insufficient evidence currently to recommend that time from menopause 
should influence decision-making. 
 
4. Use of HRT in postmenopausal women younger than 50 increases risk of breast cancer diagnosis 
i. The 2019 CGHFBC reported that commencing HRT between the ages of 40 and 50 increases risk 
of diagnosis, which contradicts advice to date.3 
ii. The control group, of age-matched postmenopausal women, however, was inappropriate as an 
early menopause reduces breast cancer risk. The population for comparison should have 
consisted of age-matched normally cycling women.  
iii. The current recommendation that years of HRT exposure in women with POI should be counted 
from the age of natural menopause (i.e. 50) should stand. Younger peri and postmenopausal 
women accrue significant symptom, quality of life, bone and cardiovascular benefits from HRT.18 
 
 
Placing breast cancer risk with HRT in perspective 
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1. HRT and other lifestyle risk factors for breast cancer 
The 2015 NG23 recommended HRT counselling should be individualized, accounting for non-
modifiable factors that determine a woman’s personal, baseline breast cancer risk, such as 
family history and exposure to modifiable risk factors, which include HRT.8 Avoidance of 
modifiable risk factors has been estimated to potentially prevent just under a quarter of breast 
cancers diagnosed in the UK female population (23%).22 In women who are overweight or obese, 
or those whose alcohol intake is elevated, the population attributable risk is 8%, which is greater 
than that associated with any HRT exposure (including risk in past users), at 5%.3,22 
Unfortunately, it is not possible to predict on an individual basis, who will benefit from 
minimising exposure to these. 
 
Table 3 summarises absolute population risk estimates by age group for obesity, alcohol intake 





Absolute excess risk per 1000 women over 5 years 
50-54 years 55-59 years 50-59 years 
Postmenopausal 
obesity24 
Highest vs lowest weight 









Alcohol25,* 35-44g / day 









Unopposed HRT  
















Combined HRT        

















* Risk with alcohol is unaffected by menopausal status. 1 unit of alcohol = 8g 
 
 
2. HRT benefits and risks 
For women experiencing menopausal symptoms, with a low underlying risk of breast cancer (i.e. 
most of the female population), the benefits of HRT in relieving symptoms, improving quality of 
life and conferring protection against cardiovascular disease and osteoporosis, will exceed 
potential harms, which include the small increased risk of breast cancer and venous thrombo-
embolic disease (VTED) diagnosis.8 In 2017, postmenopausal female deaths in England and 
Wales from ischaemic heart disease and osteoporosis combined (20,388) were almost four times 
that attributed to breast cancer (5,483).26 HRT-associated risk of VTED can be minimised by the 
use of transdermal oestrogen and possibly with combined preparations containing micronized 
progesterone or dydrogesterone.8 
 
3. HRT and mortality 
i. Breast cancer mortality 
The 2019 CGHFBC did not evaluate this relationship with HRT, although an accompanying 
research letter from the MWS investigators did.27 Here current and previous HRT use for a 
duration of more than five years was reported to be associated with an increased risk of breast 
cancer death.  Other meta-analyses, the 2015 NG23 and long-term follow-up of the randomised 
WHI study do not concur with this, although the WHI was insufficiently powered to evaluate this 
outcome.8,28,29  All evidence is open to scrutiny as collectively there is failure to provide adequate 
information about disease stage, treatment and mode of breast cancer diagnosis (i.e. whether 
screen-detected or symptomatic), which have a significant impact on prognosis. Furthermore, 
hormone sensitive breast cancer, which is promoted by HRT, has a higher long-term relapse 
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pattern compared with hormone insensitive disease. Beyond five years from diagnosis, the risk 
of recurrence is greater and beyond fourteen years, overall survival is worse in oestrogen 
receptor positive cancer.30  
ii. All-cause mortality 
In women at population risk for breast cancer, the overall mortality risk: benefit ratio favours 
unopposed and combined HRT.29,31 A recent cohort study with a follow-up of just under 18 
years, however showed time-specific differential associations in cause of HRT-associated death 
with a slightly higher breast cancer mortality, however, this was offset by lower colorectal 
cancer and cardiovascular deaths.31 This illustrates how inappropriate it is to discuss HRT 
association with breast cancer without any consideration that a risk factor for one health 
condition may protect against another. The decline in unopposed oestrogen use in the USA since 
2002, which has resulted in a significant increase in premature mortality for hysterectomized 
women aged 50 to 59 years, illustrates the relevance of fully informed patient discussion.32  
 
    
HRT in women at high baseline risk of breast cancer  
In women with a familial risk or a high-risk benign breast condition (i.e. biopsy-proven epithelial 
atypia or Lobular Carcinoma in Situ), HRT exposure has not been shown to have an additive effect on 
risk of diagnosis.13.14 Its absolute impact therefore increases as a woman’s baseline risk rises. 
Although it is recommended lifestyle and non-hormonal alternatives should be used as first-line 
management of vasomotor symptoms in high-risk women, HRT may be needed for severe, refractory 
symptoms and should be considered on an individual basis following specialist and patient 
discussion.8,13.14,33 In the absence of data, it would be difficult to justify use of HRT for indications 
other than symptom relief, where longer duration therapy would be indicated as for example in 
population-risk women with POI. The exception to this is BRCA1 and BRCA2 mutation carriers, who 
have undergone risk-reducing bilateral salpingo-oophorectomy (BSO). Here, add-back HRT has not 
been shown to diminish the risk-reducing benefit of BSO on subsequent risk of breast cancer 
diagnosis but clinical data is very limited.13,14 Further studies are needed to clarify risk with combined 
compared with unopposed HRT and the optimal duration of use.34 The current recommendation is 
that after risk-reducing BSO, add-back HRT is used until the age of an expected natural menopause, 
after which non-hormonal alternatives are used as first-line management for symptom control and 
the prevention of chronic, oestrogen-deficiency health problems.13,33 
 
 
Use of HRT after breast cancer 
Women treated for breast cancer may experience multiple symptoms including hot flushes and 
vulvo-vaginal atrophy as a consequence of a natural menopause or as a side effect of treatment 
aimed at reducing the activity or synthesis of oestrogen. Iatrogenic symptoms are not limited to 
women with hormone sensitive disease as chemotherapy-induced ovarian suppression will occur 
irrespective of the oestrogen receptor (ER) status of the primary tumour.35 Systemic HRT and low-
dose vaginal oestrogen are the most efficacious treatments but contra-indicated in women with ER 
positive disease. HRT, however, may not be without risk for those with an ER negative primary. 
Although there is high concordance in hormone receptor status between first and second primary 
breast cancers, a minority with an ER negative primary may present with an ER positive contralateral 
cancer (up to 30%) and approximately 8% may present with ER positive metastatic disease.36,37 It is 
unknown whether lifestyle risk factors have a part in this. It has been hypothesised risk will not be 
increased in women taking concurrent tamoxifen due to the very high binding affinity for the 
oestrogen receptor. However, as aromatase inhibitors reduce oestrogen production it would be 
counter-intuitive to prescribe concomitant exogenous sex hormones.8,13,14 Despite theoretical 
predictions, clinical evidence is inconclusive due to the premature closure of all three randomised 
trials of HRT in breast cancer patients, when all were underpowered. These were stopped when 
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interim analysis of one trial showed an increased risk of recurrence. Overall risk was not increased 
following interim analysis of the two other trials or meta-analysis of all three (hazard ratio 1.45, 95% 
confidence interval 0.93-2.26).38 Tibolone, a synthetic steroid with weak oestrogen, progestogen 
and/or androgen activity, has been used as an alternative to HRT for symptom relief but a large 
randomised study in breast cancer patients was also stopped prematurely due to an increased risk of 
recurrence (hazard ratio HR 1.40, 95% CI 1.14-1.70).39 
When is it appropriate to discuss systemic or vaginal HRT in the management of women with 
diagnosis of a previous breast cancer? 
NICE has taken a pragmatic approach, recommending lifestyle and non-hormonal alternatives for 
first-line management of vasomotor symptoms, recognising HRT could be considered if symptoms 
are refractory.8,35 For women with symptoms due to vulvo-vaginal atrophy if treatment with vaginal 
moisturisers fails to alleviate symptoms, vaginal oestrogen can be discussed.34 There is generally 
lower concern about systemic absorption from low and ultra-low dose vaginal oestrogen, which is 
minimal and could be acceptable where systemic therapy would not be. Neither systemic HRT nor 
low-dose vaginal oestrogen are recommended in women taking an aromatase inhibitor and with 
both, prescription should only take place after discussion between the patient, her primary health 




The British Menopause Society is of the view that the 2019 CGHFBC re-analysis provides important 
additional information on the risk of breast cancer diagnosis with HRT. The only findings which 
should influence clinical advice is that risk does not appear to be elevated with low-dose vaginal 
oestrogen and that risk may persist after systemic HRT is stopped but this can still be explained by a 
growth-promoting effect. No arbitrary limits should be placed on the dose or duration of usage of 
HRT as decisions should be made on an individualised basis after discussing the benefits and risks 
with each patient. In addition to the potential increased risks of breast cancer and VTED, they should 
also be considered in the context of the overall benefits obtained from using HRT including symptom 
management and improved quality of life as well as the cardiovascular and bone protective effects 
associated with HRT. From a research perspective, there is need for large, long-term prospective 
randomised controlled trials using conventionally regulated bio-identical HRT and further research 




1. In women with a low underlying risk of breast cancer (i.e. most of the population), the benefits 
of HRT for up to 5 years’ use for symptom relief will exceed potential harm 
• Unopposed oestrogen is associated with no, or little change in risk but this may be 
influenced by age at initiation 
• There is no evidence of a dosage effect with oestrogen 
• Vaginal oestrogen is not associated with an increased risk 
• Combined HRT can be associated with an increased risk, which appears duration dependent 
• Whilst risk with continuous combined HRT may be greater that with sequential HRT, the 
difference in risk is small and may be offset by protection against endometrial cancer 
• Avoidance of synthetic progestogens in combined preparations may minimise risk 
• Risk is limited to lean women 
• Risk associated with HRT (including past users) is less than other lifestyle risk factors for 
breast cancer 
• In women with POI, years of HRT exposure should be counted from the age of 50 




2. In women at high risk, or breast cancer survivors 
• There is no additive effect of HRT exposure in women at elevated personal risk due to a 
family history or high-risk benign breast condition.3,9  
• If the use of HRT or vaginal oestrogen is considered, this should only be for the management 
of oestrogen deficiency symptoms after discussion with the woman’s breast specialist team 
• Vaginal oestrogen can be used in women taking tamoxifen but not aromatase inhibitors. 
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